A blinded prospective study of the performance of HE4 to predict recurrence in patients with advanced ovarian cancer, peritoneal carcinoma and tubal carcinoma
A study for patients with ovarian cancer using biomarker HE-4 to predict recurrence
Sponsor: Fujirebio Diagnostics
Enrolling: Female Patients Only
Study Length: 3 Years
IRB Number: AAAN4311
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@columbia.edu
Additional Study Information: The purpose of this study is to find out if the study drug, HE4 has the potential to improve performance of biomarker CA 125 to determine recurrence of epithelial ovarian cancer before detecting the cancer clinically, surgically or through radiological scans. HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. CA 125 is a protein found on the surface of ovarian cancer cells. Study visits will consist of 5 minute blood draws.
This study is closed
Investigator
Jason Wright, MD
Do You Qualify?
Do you have diagnosis of epithelial ovarian, fallopian tube Stage II, III or IV carcinoma? Yes No
Are you currently pregnant or nursing? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE